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Nicotinamide pharmacokinetics in humans: effect of gastric acid inhibition,
comparison of rectal vs oral administration and the use of saliva for drug
monitoring
MRL Stratford', MF Dennis', P Hoskin2, H Phillips2, RJ Hodgkiss' and A Rojas'
'Gray Laboratory Cancer Research Trust and 2CRC Clinical Tumour Biology and Radiation Therapy Group, Mount Vernon
Hospital, Northwood, Middlesex HA6 2JR, UK.
Summary The effect of inhibiting gastric acid secretion on nicotinamide pharmacokinetics was studied in five
volunteers with the intent of reducing the large variations observed previously in the time to and magnitude of
peak plasma concentrations. Plasma levels were determined using a standard high-performance liquid
chromatography (HPLC) method after an oral dose of 3 g of nicotinamide either alone or preceded by
pretreatment with omeprazole. Suppression of gastric acid production had no significant effect on the rate of
uptake or on the peak levels achieved. To bypass gastric acidity, the rectal route was also assessed using a
suppository in four volunteers and one patient undergoing radiotherapy. Absorption was slow and variable and
much lower plasma levels were observed than after oral dosing. Thus, no improvement in the pharmacokinetics
of nicotinamide was observed using either of these two approaches. Parallel estimations were made using a
novel and non-invasive method for monitoring nicotinamide pharmacokinetics in saliva. A large and variable
fraction of the total amount of nicotinamide-related material in saliva was found to be nicotinic acid, a
metabolite not normally found in human plasma. This conversion was inhibited by the use of a chlorhexidine
mouthwash, indicating that the oral flora was responsible for its production. The time to peak levels of
nicotinamide or ofnicotinamide plus nicotinic acid in saliva correlated well with that in plasma. However, peak
concentrations for nicotinamide alone were significantly lower than in plasma, and very variable, whereas for
nicotinamide plus nicotinic acid saliva levels were 20-30% higher, but more consistent. Although there are
some practical difficulties in quantitatively handling saliva, the method is very useful for monitoring
nicotinamide pharmacokinetics and for assessment of compliance with nicotinamide treatment.
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Nicotinamide is currently in phase I -II clinical trials as a
radiosensitiser in combination with carbogen (Zackrisson et
al., 1994; Hoskin et al., 1995; Maazen et al., 1995). For most
chemotherapeutic agents it is important to determine the
overall exposure to the drug (area under the curve; AUC),
the maximum concentration attained and the time at which
some threshold concentration is exceeded. With a radio-
sensitiser, the time at which the peak concentration is reached
is the most critical factor, as, if the radiotherapy is given at
earlier or later times, the benefit from its use may be lost.
Studies in both normal volunteers and in patients have shown
wide variations in the time and magnitude of the peak
concentration, and that these parameters can be modified by
the type of drug formulation used (i.e. liquid vs tablet) and by
food intake (Stratford et al., 1992; Horsman et al., 1993;
Hoskin et al., 1995; Stratford et al., 1996). Overnight fasting
and the use of a liquid formulation increase the uptake of
nicotinamide and reduce variations between patients in the
time to reach peak concentration.
In routine clinical practice, fasting conditions are difficult
to achieve, unless radiotherapy takes place in the early
morning. However, since nicotinamide is a weak base (pKa
4.2), we postulated that the lower acid concentration resulting
from overnight fasting could account for some of the
improvement in the pharmacokinetic parameters observed.
In the first part of this study, suppression of gastric acid
production was investigated in five human volunteers using
omeprazole, a proton pump inhibitor and potent suppressor
of gastric acid secretion. In an alternative attempt to bypass
the problem of gastric acidity on nicotinamide uptake the use
of the rectal route was assessed using a suppository.
Plasma concentrations of nicotinamide are routinely
measured in order to determine the time to maximum
concentration (Tmnax) and the maximum concentration (Cmax)
achieved. Because of the large inter- and intrapatient
variations in the kinetic profiles (Hoskin et al., 1995),
measurements should be ideally made in all patients
receiving nicotinamide. This entails withdrawal of several
blood samples over a 24 h period and, furthermore, it is
desirable to repeat the sampling during the course of the
radiotherapy treatment. The method is invasive, inconvenient
to patients and nursing staff and expensive as it requires
skilled manpower to obtain the sample. The use of saliva as a
diagnostic fluid in pharmacokinetic studies and in particular
in therapeutic drug monitoring is very well established
(Mandel, 1993), and has been previously suggested for use
in clinical trials with radiosensitisers (Workman et al., 1978).
Therefore, we have developed a method for determining
nicotinamide levels in saliva and have compared these profiles
with those obtained in plasma.
Materials and methods
Studies were performed in both normal volunteers and
patients undergoing radiotherapy. Approval for the study
was obtained from the local Ethics Committee together with
written informed consent from the patient involved in the
study. The physical parameters of the normal volunteers and
the patient are shown in Table I.
Nicotinamide was administered orally using either 1 g
rapid release tablets (Cantassium, London), or as 2 g
suppositories supplied by the Mount Vernon Hospital
Pharmacy. Blood (2 ml) and saliva (0.5 ml) were taken
immediately before and at intervals after administration of
nicotinamide. The plasma was separated within 2 h and
stored at -20 °C until analysis. Saliva samples were
immediately placed on ice and centrifuged shortly after and
aliquots of the supernatant stored at -20 'C. Occasionally
samples were frozen and thawed before aliquoting to aid
sample handling. Concentrations of nicotinamide were
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determined in methanol extracts of plasma and saliva by
high-performance liquid chromatography (HPLC) using a
reverse-phase ion-pairing technique, which separates nicoti-
namide from its major metabolites (Stratford and Dennis,
1992).
Table I Physical parameters of the volunteers and patient
Volunteer no. Sex Weight (kg)
1 M 76.0
2 F 59.0
3 M 87.0
4 F 71.0
5 F 66.0
6 F 56.0
Patient no.
1 M 62.0
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Acid inhibition
The effect of suppressing gastric acid production on
nicotinamide uptake was studied in five volunteers following
the administration of nicotinamide either with no prior
treatment, or after 48 h pretreatment with 20 mg day-'
omeprazole (Astra Pharmaceuticals). Plasma concentrations
of nicotinamide were determined from samples collected
every 15 min for the first 2 h, and at 150, 180 and 240 min
after a single oral dose of 3 g (34-51 mg kg-1) of
nicotinamide, given 2 h after a light breakfast. Saliva was
collected in 30 ml plastic tubes at the same time as plasma
was withdrawn. After the first few samples of saliva were
processed, it was found that thorough rinsing of the mouth
following nicotinamide administration was essential to avoid
spuriously high determinations at the early time points and
that samples should be placed immediately on ice to reduce
degradation of nicotinamide. High levels of nicotinic acid
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Figure 1 Effect of omeprazole on uptake of nicotinamide after an oral dose of 3 g. A, Control; 0, +omeprazole. (a) Volunteer 1,
39 mgkg-1. (b) Volunteer 2, 51 mgkg-1. (c) Volunteer 3, 34 mgkg-l. (d) Volunteer 4, 42 mgkg-1. (e) Volunteer 5, 45 mgkg-1. (f)
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were present in the saliva, even at the earliest time point used.
Therefore, a third study was made without omeprazole in the
same volunteers using the anti-bacterial agent chlorhexidine,
which was administered as a mouthwash four times over a
24 h period (every 6 h). The last rinsing was made 3 h before
the administration of nicotinamide. In this instance only
saliva samples were monitored. Four patients were also
similarly pretreated with chlorhexidine to study the effect of
nicotinic acid on the toxicity of nicotinamide.
301
Rectal administration
Use of the rectal route for nicotinamide delivery was studied
in five subjects (four volunteers and one patient). In
volunteers a 2 g suppository of nicotinamide was adminis-
tered 2 h after a light breakfast and blood and saliva samples
were collected using the same intervals as detailed above. In
the one patient, a dose of 2 g was administered on the first
day and subsequently a dose of 4 g (2 x 2 g suppositories) on
days 8 and 11 of radiotherapy. Samples were taken less
frequently, i.e. every 30 min during the first 2 h and at 3 and
4 h.
Statistical analysis
The significance of the results was assessed using the
Student's t-test.
Results
Figure 1 shows the absorption and elimination curves after
oral nicotinamide doses of 3 g (34-51 mg kg-i) in the five
volunteers over the first 4 h either with or without
pretreatment with omeprazole. Also shown in Figure 1 (f)
are the Tmax values for each volunteer under the two
conditions. Absorption of the nicotinamide was very
consistent and rapid in four out of the five volunteers
leading to concentrations c. 20% higher than predicted from
the doses administered (Stratford et al., 1996). Volunteer no.
2, who showed rather slow absorption, attained concentra-
tions consistent with body weight. Figure 1 (f) illustrates that
there was no significant effect of omeprazole on the Tmax,
although in three out of the five, the initial rise in
concentration was faster (Figure la,d,e). Table II sum-
marises the Tmax and Cmax data (the latter both before and
after adjusting for the different body weights of the
volunteers). There was no significant difference between the
controls and the omeprazole group.
Use of the rectal route for nicotinamide delivery was
studied in five subjects (four volunteers and one patient).
Plasma nicotinamide concentrations following rectal admin-
istration of a 2 g suppository to volunteers (26-36 mg kg-i)
or 2 and 4 g to the patient (32 and 65 mg kg-') are presented
in Figure 2. There was considerable variability between the
subjects in the Tmax and Cmax achieved and concentrations
were lower than expected from previously published data.
Although uptake was fairly rapid in two out of four of the
volunteers (Figure 2a), the patient showed consistently slow
absorption of the drug (Figure 2b). Table III summarises the
data for just the normal volunteers where there was
comparable oral data, including Cmax data adjusted to take
account of the dose difference. There was a clear trend
Table II Effect of omeprazole on nicotinamide uptake after an oral
dose of 3g
tmax Cmax Cmaxa
h nmol/ml nmol/ml
Control 0.64+0.43b 621 +97 599+119
+ Omeprazole 0.81+0.67 625+29 602+81
aNormalised to a dose of40mgkg-l. bStandard deviation.
towards slower uptake of the nicotinamide, which just failed
to reach significance with the small number of volunteers.
The slower absorption was reflected in a highly significant
reduction in the peak concentration achieved.
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Figure 2 Plasma concentrations of nicotinamide after rectal
administration of 2g (a) or 2 and 4g (b) as 2g suppositories. (a)
A, volunteer 1, 26mg/kg- ;O, volunteer 4, 28mgkg-'; V,
volunteer 5, 30mgkg- , volunteer 6, 36m!kg-1. (b) Patient
1: A, 2g (32mgkg-l); *, * 4g (65mgkg- ), days 8 and 11
respectively.
Table HI A comparison of the oral and rectal routes of
administration of nicotinamide
tmax C,a,cx C
a
h nmolmr' nmolmr'
Oral 0.60+0.15b 643+127 609+82
(3g dose)
Suppository 1.31 +0.52 240+53 321+65
(2g dose) P = 0.065c P = 0.021c P = 0.008c
aNormalised to a dose of 40mgkgi. bStandard deviation.
cSignificance ofdifference between oral and rectal routes.
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Figure 3 Plasma (-) and saliva (*) nicotinamide, and saliva nicotinamide + nicotinic acid (A) concentrations after a 3g oral dose.
(a) Volunteer 1. (b) Volunteer 2. (c) Volunteer 3. (d) Volunteer 5.
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Figure 4 Plot of time to peak nicotinamide concentration in
plasma and saliva. --- slope = 1. Figures in parentheses indicate
number of observations with that value.
Saliva has also been assessed as a possible means of
monitoring plasma nicotinamide. Figure 3 shows plasma and
saliva nicotinamide concentrations in four normal volunteers
following an oral dose of 3 g of nicotinamide, and also the
combined levels of saliva nicotinamide and nicotinic acid, a
metabolite of nicotinamide not normally found in plasma.
There is considerable variability in the saliva concentrations
compared with plasma, particularly of nicotinamide alone.
However, either nicotinamide alone or the combination ofthe
parent compound with nicotinic acid predict Tmax well, but
the combination correlates better with the plasma concentra-
tions.
This latter point is illustrated in Figure 4 which
summarises the Tmax data for all cases where matching
plasma and saliva time courses were available. The figure
plots the Tmax for plasma against that for saliva. In general
there is a good correlation between the two times and in only
two cases do they differ by > 15 min.
Figure 5 plots the relationship between the peak
concentration in the plasma and the saliva for nicotinamide
alone (Figure 5a), and for nicotinamide+nicotinic acid
(Figure 5b). There is much more scatter in the data for
nicotinamide alone because of the variable contribution from
nicotinic acid. Saliva concentrations of nicotinamide were
only on average 63% of those in the plasma, with a large
standard error (> 8%) on this figure. Plotting the sum of
nicotinamide and nicotinic acid gave a much better prediction
of the plasma concentration. Saliva concentrations at the
peak were 25-30% higher than those in plasma, with a
standard error of <3%; this difference between plasma and
saliva decreased during the elimination phase.
The role of the oral flora in the appearance of nicotinic
acid in saliva is illustrated in Figure 6, where the effect in
these volunteers of a 24 h mouthwash with the anti-bacterial
agent chlorhexidine on this conversion is presented. In
control saliva, nicotinic acid comprises a large but very
variable proportion of the total nicotinamide-related materi-
al, in excess of 90% in some samples. Use of the
chlorhexidine mouthwash resulted in a large decrease in
nicotinic acid in three out of the four volunteers. However,
the amount of nicotinamide-related material (i.e. nicotina-
mide+nicotinic acid) remained constant, as evidenced by the
similarity between the curves for nicotinamide+nicotinic acid
in a control volunteer, and nicotinamide alone after
chlorhexidine (Figure 7).
Nicotinic acid is inactive as a sensitiser, but is
physiologically active, causing headaches and nausea,
symptoms very similar to those seen in our patients after
nicotinamide. We therefore carried out a limited investigation
into whether the toxicity induced by nicotinamide could in
some way be related to the high local concentration of
nicotinic acid in the mouth and thus the upper gastro-
a
800
600
400
^:200
E
EO0
2
-
c C 0
: 600
0
c
0 0
400
200
0
1nnn
D ,cNicotinamide pharmacokinetics in humans
MRL Stratford et al
20
a
I
E
C
b
800
400
(S 204
() 154
104
54
0 200 400 600 800 1000 1200
Plasma Cmax (nmol ml-1)
Figure 5 Plot of maximum plasma nicotinamide concentration
and (a) saliva nicotinamide alone, slope =0.63 +0.05 (s.e.). (b)
Saliva nicotinamide +nicotinic acid, slope = 1.28 +0.03 (s.e.).
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Figure 6 Effect of chlorhexidine on oral metabolism of nicotinamide to
Volunteer 1. (b) Volunteer 2. (c) Volunteer 3. (d) Volunteer 5.
intestinal tract, by giving four patients a chlorhexidine
mouthwash before the nicotinamide. However, this was
ineffective in reducing toxicity, and three of the patients
failed to complete their course of nicotinamide.
An attempt was made to determine the nicotinamide
concentration in the saliva using a simple spectrophotometric
assay on diluted saliva (data not shown). However, this
method suffered from two severe limitations that would
minimise its usefulness as a rapid analytical technique.
Firstly, at the wavelength required to monitor nicotinamide
(260 nm), there is considerable but variable absorbance from
the saliva, which makes background subtraction difficult,
and, secondly, the extinction coefficients of nicotinamide and
nicotinic acid at 260 nm are different, although this difference
can be minimised by the addition of methanol, which also
deproteinises the sample.
Discussion
Nicotinamide is a very weakly basic drug (pKa 4.2) which will
be protonated, and therefore bear a positive charge, in the
acidic conditions of the stomach. In the absence of a specific
carrier for nicotinamide, passage by passive diffusion across
the hydrophobic cell membrane lining the gut wall would be
expected to be slow. We, and other investigators (Stratford et
al., 1992; 1995; Horsman et al., 1993) have shown that
overnight fasting is effective in promoting rapid nicotinamide
absorption. If this were a reflection of low gastric acid
production, pharmacological suppression of its secretion with
omeprazole would also improve the rate of uptake of
nicotinamide. However, no effect of omeprazole was seen on
the time at which peak concentrations were reached, although
in four out of the five volunteers, absorption in the control
conditions was rapid, with peak concentrations being reached
in 0.5 h; this would make it difficult to detect a small effect of
omeprazole. However, in one volunteer, peak concentrations
b
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Figure 7 Effect of chlorhexidine on salivary nicotinamide
concentration. 0. 0. Control. A. A. +Chlorhexidine. Open
symbols nicotinamide alone. closed symbols nicotina-
mide -4- nicotinic acid.
were not reached until 1.5 h; even so. the omeprazole had no
beneficial effect on the rate ofnicotinamide uptake; indeed, the
peak was reached some 0.75 h later.
In an alternative attempt to bypass the problem of gastric
acidity on nicotmamide uptake. the use of the rectal route
was assessed. However, in no case was very rapid uptake
seen, and considerable variation was observed in the time at
which peak concentrations were found. In addition. the
rather flat plasma concentration proffiles seen in the patient
between 2 and 4 h suggested that drug was continuing to be
released over a prolonged time period. Absorption may have
been incomplete in all the subjects, as implied by the peak
levels, which were lower than in previous studies with this
dose, particularly in the patient but also in the volunteers.
From previously published data (Stratford et al., 1996). the
2 g suppository, which corresponded to doses between 26 and
36 mg kg-1 would have been expected to yield levels between
300 and 400 nmol ml-'. whereas the concentration following
the 4 g (65 mg kg-') dose to the patient should have been
double the 300-400 nmol ml-' actually obtained. As it
would not be feasible to administer a larger dose than this.
the rectal route is unlikely to be of value as a means of giving
nicotinamide as a radiosensitiser.
It is thought that radiosensitisation with nicotinamide is
maximal at the time of peak plasma concentration. As this
time is unpredictable. a simple yet reliable means of
monitoring nicotinamide levels would be of great value.
Salivary concentrations were therefore evaluated in this
study. as an alternative rapid and less invasive means of
assessing the time to reach peak concentrations. Measuring
only nicotinamide in saliva gave a poor correlation with
plasma concentrations. although the time to peak was well
predicted. Saliva concentrations of nicotinamide alone were
on average 63% of those in the plasma. while nicotina-
mide+nicotinic acid concentrations at the peak were 125-
130% of those in plasma, with much less scatter.
As nicotinic acid is not detectable in plasma after
administration of nicotinamide, three other possible sources
of the nicotinic acid were considered. namely active secretion
by the salivary glands. conversion by the oral flora or the
occurrence of ex vivo metabolism. The last was ruled out by
assessing the effect of cooling the samples on ice followed by
rapid processing and analysis. Samples were also deliberately
incubated at 37 "C; any further conversion to mucotinic acid
was extremely slow. The major source of metabolism was
found to be the bacterial flora in the mouth. as the process
was almost completely abolished by the use of a chlorhex-
idine mouthwash. It is noteworthy that the volunteer who
showed both the lowest initial percentage of nicotinic acid in
the saliva, and the smallest effect of stenrlisation with
chlorhexidine was the only regular user of a mouthwash.
This may have had the dual effect of reducing the amount of
oral flora. but also of creating a population that was more
resistant to chlorhexidine than normal. The extent of the
metabolism of nicotinamide to nicotinic acid in the short
contact time of the saliva in the oral cavity seems remarkable.
although this phenomenon of rapid metabolism has not
proved to be a major problem in other drug studies in which
saliva has been used as a pharmacokinetic marker. However.
the metabolism appears to be unrelated to toxicity. and in
any case can be prevented by the simple use of a sterilising
mouthwash, commonly used during radiotherapy. This could
be used to simplify the analysis of saliva. as only
nicotinamide would need to be determined.
In summary, these data show that inhibiting gastric acid
production does not improve the uptake of nicotinamide. nor
does the use of a suppository offer any significant benefit.
Handling saliva quantitatively is a potential problem because
ofits viscosity, although freezing and thawing the sample can
greatly improve matters (Ellison. 1993). In addition, patients
receiving radiotherapy treatment fields that include the
salivary glands frequently have reduced saliva flow, which
may make sampling difficult. However, monitoring of
nicotinamide and nicotinic acid concentrations in saliva
may be a very useful and non-invasive means of assessing
drug uptake and compliance.
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